Article Text

other Versions

PDF
Intracameral Bevacizumab Effectively Reduces Aqueous VEGF Levels in Neovascular Glaucoma
  1. Sandeep Grover (sandgrov{at}gmail.com),
  2. Shailesh K Gupta (shailesh.gupta{at}jax.ufl.edu),
  3. Rajesh K Sharma (rajesh.sharma{at}jax.ufl.edu),
  4. Vikram S Brar (vikram.brar{at}jax.ufl.edu),
  5. Kakarla V Chalam (kchalam{at}jax.ufl.edu)
  1. University of Florida, United States
  2. University of Florida, United States
  3. University of Florida, United States
  4. University of Florida, United States
  5. University of Florida, United States

    Abstract

    Vascular endothelial growth factor (VEGF) levels in both the aqueous and vitreous are elevated in ocular ischemia secondary to exudative age-related macular degeneration, diabetes mellitus, and other retinal vascular diseases.1,2 Retinal ischemia upregulates VEGF production resulting in neovascularization of the retina and the iris (NVI). VEGF is significantly elevated in neovascular glaucoma (NVG).3

    In the following case series, we demonstrate elevated aqueous VEGF levels in two patients with NVI that significantly declined with concurrent resolution of NVI following off-label intracameral injections of bevacizumab.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.